ADC Therapeutics SA

These are tough times for start-ups to raise cash on this side of the Atlantic but the money is there if you are developing a novel class of payloads in the hot space of antibody-drug conjugates (ADC)

Verona Pharma plc entered into agreements that give the company access to as much as $650m in new debt and other financing, bringing its new cash potential to more than $1bn after starting the year w

While multiple new biologics for treating diffuse large B-cell lymphoma (DLBCL) have come onto the market in recent years, Pfizer Inc. is highlighting data in the disease for Adcetris (brentuximab v

Medicines that are awarded orphan drug designations in the EU benefit from a number of rewards, including 10 years of market exclusivity and reduced regulatory fees. However, drugs that are used to tr